
Regulation (EU) 2024/1938 on substances of human origin (SoHO) was published in the Official Journal on 17 July 2024 and applies from 7 August 2027,[…]

Herbal products sit on a regulatory boundary. Positioned as food supplements, they cannot make medicinal claims. Positioned as medicines, they need an authorisation or a[…]

Targeted therapies increasingly depend on a test that decides which patients should receive them. Under the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746, that[…]

The European Health Data Space Regulation, Regulation (EU) 2025/327, entered into force on 26 March 2025. Its obligations apply in stages from 2027 to 2035,[…]

Since 15 January 2026, every new variation submitted in the EU has been assessed against the revised Variations Guidelines that accompany Regulation (EU) 2024/1701. The[…]

Every package leaflet submitted in the EU must reflect the results of consultation with target patient groups. For many marketing authorisation applicants, that consultation means[…]

Two biosimilars received positive CHMP opinions in October 2026: Fovlussea (ranibizumab) for wet age-related macular degeneration and other visual impairments, and Neuzafy (filgrastim) for neutropenia.[…]

The October 2026 CHMP meeting recommended five extensions of indication, including for Talvey, Tryngolza, Tukysa, Kyinsu and a pandemic influenza H5N1 vaccine. EMA counts 97[…]

With the reform of EU pharmaceutical legislation moving towards publication, companies have a window to prepare. A phased approach avoids both premature spending and last-minute[…]

Most of the EU pharmaceutical reform will apply about two years after entry into force, but some provisions are expected to take effect immediately. Published[…]